甲泼尼龙联合恩替卡韦治疗原发性肾病综合征合并乙肝病毒感染的临床疗效和安全性分析

Clinical efficacy and safety of methylprednisolone combined with entecavir in treatment of primary nephrotic syndrome complicated with hepatitis B virus infection

目的:探究甲泼尼龙和恩替卡韦联合治疗原发性肾病综合征合并乙肝病毒感染的治疗效果。方法:收治原发性肾病综合征合并乙肝病毒感染患者28例,分为两组,每组各14例。对照组采用单纯甲泼尼龙进行治疗,试验组在此基础上加用恩替卡韦进行治疗,对比两组患者的治疗总有效率。结果:试验组患者的治疗总有效率较对照组明显更高,差异有统计学意义(P<0.05)。结论:将甲泼尼龙联合恩替卡韦联合用于治疗原发性肾病综合征合并乙肝病毒感染患者的治疗方案中,能够有效改善患者的治疗有效性。

Objective:To explore the therapeutic effect of methylprednisolone and entecavir in the treatment of primary nephrotic syndrome complicated with hepatitis B virus infection.Methods:28 patients with primary nephrotic syndrome complicated with hepatitis B virus infection were selected,they were divided into the two groups on average,the control group was treated with simple methylprednisolone,the experimental group was treated with entecavir on the basis of the control group,the total effectiveness of the two groups of patients was compared.Results:The total effective rate of the experimental group was significantly higher than that of the control group,and the difference between the two groups was statistically significant(P<0.05).Conclusion:The combination of methylprednisolone and entecavir in the treatment of patients with primary nephrotic syndrome and hepatitis B virus infection can effectively improve the effectiveness of the patients.